Researchers at the University of Alberta have said that a drug used to treat deadly coronavirus infections in cats can potentially be an effective treatment against SARS-CoV-2. The results of the experiment published in the journal Nature Communications on August 27, 2020.
The study aided scientists at the U.S. Department of Energy’s SLAC National Accelerator Laboratory, paves the way for human clinical trials.
“This drug is very likely to work in humans, so we’re encouraged that it will be an effective treatment for COVID-19 patients,” said Joanne Lemieux, a professor of biochemistry at the University of Alberta and the study’s senior author.
GC376 works interfering with a virus’ ability to replicate in cats, thus ending the virus. Derivatives of the following drug were first studied in 2003 after the outbreak of severe acute respiratory syndrome (SARS). It was further developed veterinary researchers who showed it cures fatal feline affliction.
Visual Illustration of the Results of the Experiment
(The above article has been written from inferences taken the Journal published in Nature Communications)